Patient guide · Reviewed June 2026
GLP-1 Therapy and Muscle Loss — Why Protein and Resistance Training Matter
GLP-1 medications produce substantial weight loss — but not all of that weight is fat. A meaningful portion of it is lean tissue, including muscle. Here's what the trial data actually shows, why it matters, and what's been shown to help protect your muscle mass while still losing weight.
Published 2026-06-01 · Clinically reviewed 2026-06-03
Patient guide · Reviewed June 2026
What the trial data shows about what's actually being lost
Body composition substudies within major GLP-1 and dual-agonist clinical trials — using DXA scanning to measure exactly what kind of tissue is being lost, not…
Body composition substudies within major GLP-1 and dual-agonist clinical trials — using DXA scanning to measure exactly what kind of tissue is being lost, not just total weight — reveal that a significant proportion of weight reduction consists of lean body mass, including skeletal muscle, rather than fat mass alone.
In the STEP 1 trial (semaglutide 2.4 mg), lean mass accounted for approximately 30% to 39% of total weight lost. In the SURMOUNT-1 DXA substudy (tirzepatide), approximately 26% of total weight reduction was lean tissue — an absolute loss of 15.9 kg of fat mass alongside 5.6 kg of lean mass over 72 weeks.
Is this actually a problem? The context that matters
Those percentages can sound alarming in isolation, but clinical endocrinologists and exercise physiologists point to an important comparison: this composition is comparable to, or slightly better than, the lean mass loss of 20% to 35% typically observed with severe calorie restriction or bariatric surgery. In other words, losing some lean mass alongside fat mass isn't a problem unique to GLP-1 medications — it's a feature of significant weight loss generally, by whatever method it's achieved.
It's also worth understanding that not all of what's measured as "lean mass" loss is functional muscle tissue. A meaningful portion reflects physiological adaptation — changes in total body water, intracellular fluid volume, and a reduction in highly metabolically active liver tissue (which shrinks as fatty liver improves) — rather than a pathological loss of the muscle you actually use for strength and mobility.
Patient guide · Reviewed June 2026
Where the real risk lies — and who should pay closest attention
The genuine concern is sarcopenic obesity — a combination of significant fat loss alongside disproportionate muscle loss, which can leave someone at a lower…
The genuine concern is sarcopenic obesity — a combination of significant fat loss alongside disproportionate muscle loss, which can leave someone at a lower body weight but with reduced functional strength. This risk is particularly relevant for older adults, who start from a higher baseline risk of frailty, impaired mobility, and metabolic adaptation, and who have less physiological reserve to rebuild lost muscle compared with younger patients.
If you're older and starting GLP-1 therapy, this is a genuinely important conversation to have with your doctor early — not a reason to avoid treatment, but a reason to actively plan for muscle preservation from day one rather than as an afterthought.
Increased protein intake
Guidelines recommend patients on incretin therapy consume 1.2 to 1.6 grams of protein per kilogram of body weight daily. For context, that's equivalent to roughly 110 to 145 grams of protein daily for a 200-pound (~90 kg) patient — meaningfully more than typical general population protein recommendations, and often more than someone eating less overall (due to GLP-1-induced appetite suppression) might naturally consume without deliberately prioritising protein-rich foods.
This is one of the most practical, immediately actionable things to focus on if you're concerned about muscle preservation: because GLP-1 medications reduce overall appetite and food volume, getting enough protein often requires actively prioritising protein-dense foods early in meals, rather than assuming it will happen incidentally.
Patient guide · Reviewed June 2026
Structured resistance training
Nutritional intake alone isn't sufficient — muscle needs a mechanical stimulus to be preserved during a sustained calorie deficit. Clinical guidance pairs the…
Nutritional intake alone isn't sufficient — muscle needs a mechanical stimulus to be preserved during a sustained calorie deficit. Clinical guidance pairs the increased protein target with structured resistance training, 2 to 3 sessions per week, targeting major muscle groups.
This doesn't need to mean an intense gym program if that's not accessible or appealing to you — the key principle is regular, structured resistance work (which can include bodyweight exercises, resistance bands, or supervised gym-based training) rather than relying on incidental daily activity alone.
What this means practically if you're starting GLP-1 therapy
- Don't wait for muscle loss to become noticeable before addressing it. The evidence-based approach is to build protein intake and resistance training into your plan from the start of treatment, not in response to a problem that's already developed.
- Track your protein intake deliberately, particularly in the early weeks when appetite suppression is often strongest and total food intake drops the most.
- If you're not currently doing any resistance training, this is a good moment to start — even a modest, consistent routine is well-evidenced to help, and a referral to an exercise physiologist may be worth discussing with your GP if you're unsure where to begin.
- If you're an older adult, raise muscle preservation specifically and proactively with your prescriber — this is the population where the stakes of getting this wrong are highest.
- A dietitian experienced in GLP-1 therapy can help translate the 1.2–1.6 g/kg protein target into a realistic, sustainable eating pattern that works alongside reduced appetite, rather than fighting against it.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
Does Ozempic cause muscle loss?
A portion of weight lost on GLP-1 medications is lean mass — roughly 26–39% in major trials. High protein intake and resistance training help preserve muscle.
How much protein should I eat on Wegovy or Mounjaro?
Clinical guidance recommends 1.2–1.6 g protein per kg body weight daily during active weight loss on incretin therapy.
Do I need to lift weights on GLP-1?
Structured resistance training 2–3 times per week is recommended alongside protein intake to preserve muscle during a calorie deficit.
Are older adults at higher risk of sarcopenia on GLP-1?
Yes. Older adults have less reserve to rebuild lost muscle — plan protein and resistance training from day one, not after problems appear.
STEP 1 trial DXA body composition substudy (semaglutide 2.4 mg); SURMOUNT-1 DXA body composition substudy (tirzepatide); published clinical guidance on protein intake and resistance training during incretin-based weight loss therapy; comparative data on lean mass loss in calorie restriction and bariatric surgery.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.